Estrone and 17beta-estradiol reverse breast cancer resistance protein-mediated multidrug resistance.

Yasuo Imai, Satomi Tsukahara, Etsuko Ishikawa, Takashi Tsuruo, Yoshikazu Sugimoto

Division of Molecular Biotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research,Toshima-ku, Tokyo 170-8455, Japan.

Japanese journal of cancer research : Gann 2002 Mar

filter terms:

Breast cancer resistance protein (BCRP), an adenosine triphosphate-binding cassette transporter, confers resistance to a series of anticancer reagents, including mitoxantrone, SN-38 and topotecan. In the present study, we found that estrone and 17beta-estradiol potentiated the cytotoxicity of mitoxantrone, SN-38 and topotecan in BCRP-transduced K562 cells (K562 / BCRP). These estrogens showed only a marginal effect, or none, in parental K562 cells. Estrone and 17beta-estradiol increased the cellular accumulation of topotecan in K562 / BCRP cells, but not in K562 cells, suggesting that these estrogens inhibit the BCRP-mediated drug efflux and overcome drug resistance.

Citation

Yasuo Imai, Satomi Tsukahara, Etsuko Ishikawa, Takashi Tsuruo, Yoshikazu Sugimoto. Estrone and 17beta-estradiol reverse breast cancer resistance protein-mediated multidrug resistance. Japanese journal of cancer research : Gann. 2002 Mar;93(3):231-5